Navigation Links
Cardica Announces Fiscal 2013 Second Quarter Financial Results
Date:1/31/2013

REDWOOD CITY, Calif., Jan. 31, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced financial results for its fiscal second quarter and six months ended December 31, 2012. Cardica's management will hold a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.

"Having shipped our first commercial units of the MicroCutter XCHANGE™ 30, with additional orders in process for early adopters, we plan to extend our commercial launch gradually while making selective improvements to ensure broad reliability and clinical adoption in Europe," said Bernard A. Hausen , M.D., Ph.D., president and chief executive officer of Cardica. "At the same time, we intend to enroll additional patients in our European clinical trial using the commercial version of our XCHANGE 30 in the weeks ahead, with a planned enrollment completion in the second quarter of calendar year 2013."

Recent Highlights and Accomplishments

  • Shipped 30 MicroCutter XCHANGE™ 30 devices and 108 XCHANGE™ 30 cartridges, to DACH Medical Group, the company's distributor in Germany, Austria and Switzerland in the fiscal 2013 second quarter
  • Enrolled additional patients in the company's European clinical trial of the MicroCutter XCHANGE 30 devices; the commercial XCHANGE 30 device will be used for all remaining patients enrolled in the study;
  • Added and trained two new trial sites in Germany for Cardica's European clinical study, bringing the total number of sites having or actively enrolling patients to seven;
  • Completed over 700 deployments in more than 250 procedures with the XCHANGE 30 device since May
    '/>"/>

  • SOURCE Cardica, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
    2. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
    3. Cardica Announces Fiscal 2013 First Quarter Financial Results
    4. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
    5. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
    6. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
    7. Cardica Announces Fiscal 2012 Third Quarter Financial Results
    8. Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
    9. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    11. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
    (Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
    (Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
    Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
    ... N.J., Feb. 3, 2011 BioNeutral Group, Inc. (OTC ... science technology-based company, today announced the formation of BioNeutral ... Inc., and the appointment of Frank Battafarano as the ... BioNeutral Services will market and distribute a ...
    ... 2011 A VANIR Pharmaceuticals, Inc. ... the three months ended December 31, 2010. For the ... $12.1 million, or $0.11 loss per share, compared with a net ... same period in fiscal 2010. Net revenues consisting primarily of royalty ...
    Cached Medicine Technology:BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 2BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 2AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 4AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 5AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 6
    (Date:8/22/2014)... August 22, 2014 Ticket Down ... in Kalamazoo, New Orleans, Albuquerque and Rapid City. For ... “Long Island Medium,” Theresa Caputo, allows just that. Caputo was ... is part of a close knit family who began to ... a spiritual healer, realized she had a chance to do ...
    (Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” ... Luciana, is finding it challenging to stay on top of ... of hundreds of students, so the editing of the episodes ... completed, and she recently entered it into the festival circuit. ... her husband, actor/screenwriter Gregory Graham , the aging and ...
    (Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
    (Date:8/22/2014)... Each year approx. 265,000 Danes are acutely admitted to ... from Aarhus University and Aarhus University Hospital now shows ... fourth patient are sent home again without receiving ... the acute hospitalisation., "Naturally, there is no need for ... that there is a serious illness. So some patients ...
    (Date:8/22/2014)... of Alzheimer,s disease can be slowed and some ... that is found in pomegranate. Also, the ... arthritis and Parkinson,s disease could be reduced, according ... by University of Huddersfield scientist Dr Olumayokun Olajide, ... products. , Now, a new phase of research ...
    Breaking Medicine News(10 mins):Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2
    ... and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals,today ... healthy subjects in,a Phase I study of AFN-1252, ... class of fatty acid biosyntheis inhibitors. The study ... of a single,escalating oral dose. Affinium believes that ...
    ... , The doctoral thesis of Isaac Manuel lvarez Ruiz ... Signal Theory, Telematics, and Communication , and Department of Surgery ... and directed by Professors ngel de la Torre Vega ... work includes improving the acquisition of Compound Action Potential records, carrying ...
    ... of Health,Dr. Calvin B. Johnson today met with ... discuss Governor Edward G. Rendell,s plan to,provide access ... uninsured,adults through his "Cover All Pennsylvanians" proposal., ... prevent disease,successfully manage chronic diseases such as diabetes ...
    ... fleet golf car and the role of MES, ... execution systems (MES) for the integrated enterprise,announced today that ... E-Z-GO Fleet Golf Car: Integrating Manufacturing,Execution with New Product ... March 6, 2008 at 2:00 p.m. EST., During ...
    ... retained 1 year after therapy , , TUESDAY, March 4 ... shows promise in adults, say American and Chinese researchers ... , Lazy eye, also known as amblyopia, has been ... condition, especially those in developing countries, are diagnosed too ...
    ... Promotes National Kidney Month Programs to,Combat Spread of ... WASHINGTON, March 4 DaVita Patient Citizens,(DPC) ... more than 22,000,dialysis and pre-dialysis patients and family ... all dialysis patients through education and,advocacy -- enthusiastically ...
    Cached Medicine News:Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 2Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 3Health News:Health Secretary's Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 2Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 2Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 3Health News:New Treatment for 'Lazy Eye' Shows Promise 2Health News:Kidney Patient Advocacy Community Joins National Effort to Raise Awareness about Health Crisis Impacting more than 26 Million Americans 2
    Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
    ... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
    ... bone content (93% by volume) of any ... excellent handling characteristics, which will enhance any ... alone or as a graft extender for ... The high molecular weight biocompatible carrier allows ...
    ... DS Strep A is a qualitative assay for ... swabs. The ICON DS Strep A test excels ... rare and low positive colonization samples. This CLIA ... outstanding performance, ICON DS Strep A leaves little ...
    Medicine Products: